HIGH-THROUGHPUT SCREENING AND DYNAMIC STUDIES OF SELECTED COMPOUNDS AGAINST SARS-COV-2

Authors

  • RATUL BHOWMIK Medicinal Chemistry and Molecular Modelling Lab, Department of Pharmaceutical Chemistry, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India
  • RANAJIT NATH Department of Pharmaceutics, NSHM Knowledge Campus, Kolkata-Group of Institutions, Kolkata, West Bengal, India
  • SAMEER SHARMA Department of Bioinformatics, BioNome Private Limited, Bengaluru, India
  • RATNA ROY Department of Pharmacology, NSHM Knowledge Campus, Kolkata-Group of Institutions, Kolkata, West Bengal, India
  • RIYA BISWAS Department of Pharmaceutical Technology, Jadavpur University, Kolkata, West Bengal, India

DOI:

https://doi.org/10.22159/ijap.2022v14i1.43105

Keywords:

Molecular Docking Phytocompounds, Dynamic Simulation, Drug Discovery

Abstract

Objective: This study was aimed to analyze the inhibitory effect of the drugs used in nanocarrier as well as nanoparticles formulation based drug delivery system selected from PubChem database literature against 3CLpro (3C-like protease) receptor of SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) by implementing several in silico analysis techniques.

Methods: This paper detailed a molecular docking-based virtual screening of 5240 compounds previously utilized in nanoparticle and nanocarrier drug delivery systems utilizing AutoDock Vina software on 3CL protease to discover potential inhibitors using a molecular docking technique.                                                                                                  

Results: According to the results of the screening, the top two compounds, PubChem Id 58823276 and PubChem Id 60838 exhibited a high affinity for the 3CL protease binding region. Their binding affinities were -9.6 and -8.5 kJ/mol, indicating that they were tightly bound to the target receptor, respectively. These results outperformed those obtained using the co-crystallized native ligand, which exhibited a binding affinity of -7.4 kJ/mol. PubChem Id 60838, the main hit compound in terms of both binding affinity and ADMET analysis, displayed substantial deformability after MD simulation. As a result of the VS and molecular docking techniques, novel 3CL protease inhibitors from the PubChem database were discovered using the Lipinski rule of five and functional molecular contacts with the target protein, as evidenced by the findings of this work.

Conclusion: The findings suggest that the compounds discovered may represent attractive opportunities for the development of COVID-19 3CLpro inhibitors and that they need further evaluation and investigation.

Downloads

Download data is not yet available.

References

Biju P, Pallavi K, Revadigar V, Dsouza S, Asif M, Gulzar I. A REVIEW ON THE IMPACT OF THE COVID-19 PANDEMIC ON THE HEALTH CARE SECTOR. Int J Pharm Pharm sciences. 2021;13(10):1–6.

Jamalipour Soufi G, Iravani S. Potential inhibitors of SARS-CoV-2: recent advances. J Drug Target [Internet]. 2021;29(4):349–64. Available from: http://dx.doi.org/10.1080/1061186X.2020.1853736

Rathnayake AD, Zheng J, Kim Y, Perera KD, Mackin S, Meyerholz DK, et al. 3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV–infected mice. Sci Transl Med. 2020;12(557):1–16.

Su H, Yao S, Zhao W, Zhang Y, Liu J, Shao Q, et al. Identification of pyrogallol as a warhead in design of covalent inhibitors for the SARS-CoV-2 3CL protease. Nat Commun [Internet]. 2021;12(1):1–12. Available from: http://dx.doi.org/10.1038/s41467-021-23751-3

Kontoyianni M. Docking and virtual screening in drug discovery. Methods Mol Biol. 2017;1647(August):255–66.

Kim S, Thiessen PA, Bolton EE, Chen J, Fu G, Gindulyte A, et al. PubChem substance and compound databases. Nucleic Acids Res. 2016;44(D1):D1202–13.

Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, et al. The Protein Data Bank. Vol. 28, Nucleic Acids Research. 2000. p. 235–42.

Trott O, Olson AJ. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2009;31(2):455–61.

Visualizer DS. v4. 0.100. 13345. In: Accelrys Software Inc. 2005.

Client DS, Studio D, Discovery T, Client S. Introduction to the Discovery Studio Client. :1–7.

Daina A, Michielin O, Zoete V. SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep. 2017;7(October):1–13.

Lee S., Chang G., Lee I., Chung J., Sung K., No K. The PreADME: pc-based program for batch prediction of ADME properties. EuroQSAR. 2004;9.

Molinspiration cheminformatics. Choice Rev Online. 2006;43(11).

Bhowmik R, Roy S, Sengupta S, Sharma S. Biocomputational and Pharmacological Analysis of Phytochemicals From Zingiber Officinale ( Ginger ), Allium Sativum ( Garlic ), and Murrayakoenigii ( Curry .... Zingiber Officinale ( Ginger ), Allium Sativum ( Garlic ), and Murrayakoenigii ( Curry Leaf ). Int J Appl Pharm. 2021;13(5):280–6.

Daina A, Zoete V. A BOILED-Egg To Predict Gastrointestinal Absorption and Brain Penetration of Small Molecules. ChemMedChem. 2016;11(May):1117–21.

Kwatra B, Roy R, Bhowmik R, Sengupta S. DRUG REPURPOSING : IN SILICO MODELING OF COVID-19. Res J Life Sci Bioinformatics, Pharm Chem Sci. 2021;7(2):19–40.

Singh DD, Han I, Choi EH, Yadav DK. Recent Advances in Pathophysiology, Drug Development and Future Perspectives of SARS-CoV-2. Front Cell Dev Biol. 2020;8(1124):1–54.

Shaji J, Shaikh M. Drug-Resistant Tuberculosis: Recent Approach in Polymer Based Nanomedicine. Int J Pharm Pharm sciences. 2016;8(10):1–6.

Nath R, Roy R, Mondal B, Bhattacharya B, Ravi L. Nanoparticle’s Significance as Antibacterial Agents & Other Pharmaceutical Applications and Their Limitations: A Critical Review. J Pharm Res Int. 2021;33(38B):8–27.

Published

02-11-2021

How to Cite

BHOWMIK, R., NATH, R., SHARMA, S., ROY, R., & BISWAS, R. (2021). HIGH-THROUGHPUT SCREENING AND DYNAMIC STUDIES OF SELECTED COMPOUNDS AGAINST SARS-COV-2. International Journal of Applied Pharmaceutics, 14(1). https://doi.org/10.22159/ijap.2022v14i1.43105

Issue

Section

Original Article(s)